PND14 Budgetary Impact of the Treatment of Relapsing-Remitting Multiple Sclerosis in Spain

Value in Health - United Kingdom
doi 10.1016/j.jval.2012.08.1938
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Intestinal Permeability in Relapsing-Remitting Multiple Sclerosis

Neurotherapeutics
NeurologyPharmacology
2017English

Natalizumab: A New Treatment for Relapsing Remitting Multiple Sclerosis

Therapeutics and Clinical Risk Management
Chemical HealthPharmacologySafetyMedicineToxicologySafety ResearchPharmaceutics
2007English

Budget Impact Analysis of Delayed-Release Dimethylfumarate in the Treatment of Relapsing-Remitting Multiple Sclerosis in Italy

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Impact of the McDonald Criteria 2017 on Early Diagnosis of Relapsing-Remitting Multiple Sclerosis

Frontiers in Neurology
Neurology
2019English

Pnd60 - Cost-Effectiveness of Teriflunomide for the Treatment of Relapsing-Remitting Multiple Sclerosis in Greece

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Alemtuzumab: A Review of Efficacy and Risks in the Treatment of Relapsing Remitting Multiple Sclerosis

Therapeutics and Clinical Risk Management
2017English

Progressive Multifocal Leukoencephalopathy and Relapsing-Remitting Multiple Sclerosis

Archives of Neurology
2009English

Disease-Modifying Therapies in Relapsing–remitting Multiple Sclerosis

Neuropsychiatric Disease and Treatment
PsychiatryMental HealthBiological Psychiatry
2010English

Stressful Events Increase Exacerbations in Relapsing-Remitting Multiple Sclerosis

BMJ
2003English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy